Table 3.
Effect of ACR and eGFR Group on Progression to ESRD by Cause of Kidney Disease
| Cystic Kidney Disease | Glomerulonephritis | Diabetic Nephropathy | Other Recorded Diagnoses | |
|---|---|---|---|---|
| Urinary ACR (mg/g)a | ||||
| <30 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| ≥30-<300 | 1.18 (0.88-1.58) | 2.39 (1.03-5.54) | 1.64 (0.79-3.41) | 1.39 (1.05-1.84) |
| ≥300 | 1.21 (0.87-1.69) | 7.26 (3.22-16.36) | 5.85 (2.98-11.49) | 3.91 (2.99-5.10) |
| eGFR (mL/min/1.73 m2)b | ||||
| <15 | 13.11 (9.13-18.82) | 20.41 (13.98-29.79) | 20.58 (14.07-30.11) | 23.56 (17.95-30.92) |
| ≥15-<30 | 4.81 (3.41-6.80) | 4.71 (3.24-6.84) | 3.95 (2.74-5.68) | 5.13 (3.94-6.68) |
| ≥30 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
Note: Values shown are relative risk (95% confidence interval).
Abbreviations: ACR, albumin-creatinine ratio; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease.
Interactions between albuminuria group and diagnoses of cystic kidney disease, glomerulonephritis, and diabetic nephropathy, after adjustment for age, sex, country, race, treatment allocation, prior diseases and medication, lipid levels, smoking, blood pressure, body mass index, phosphate level, hemoglobin level, and eGFR.
Interactions between eGFR group and diagnoses of cystic kidney disease, glomerulonephritis, and diabetic nephropathy, after adjustment for age, sex, country, race, treatment allocation, prior diseases and medication, lipid levels, smoking, blood pressure, body mass index, phosphate level, hemoglobin level, and ACR.